Mazdutide
Extensamente estudadoDual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation.
Dados moleculares e de pesquisa
- Sequência
- 33-amino acid linear synthetic peptide
- Peso molecular
- 4,563.1 Da
- Meia-vida
- 6-8 days
- Vias (pesquisa)
- injectable
- Armazenamento
- Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution
Overview
First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.
Mechanism of action
Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.
Key research findings
- Up to 20% body weight loss
- Superior glycemic control versus semaglutide
- Increased energy expenditure via glucagon receptor activation
- Improved cardiometabolic markers (BP, lipids, liver fat)
- Once-weekly injection convenience
Research applications
Weight Loss
- Severe Obesity Management — GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.
- Metabolic Syndrome Improvement — Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).
- Liver Fat Reduction — Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.
Type 2 Diabetes
- Glycemic Control — HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.
- Dual Endpoint Achievement — 48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.
Cardiovascular
- Blood Pressure Reduction — Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.
- Lipid Profile Enhancement — Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.
FAQ de Mazdutide
How much weight does mazdutide cause compared to semaglutide?+
Mazdutide demonstrated 20.1% weight loss over 60 weeks in Phase 3 trials (GLORY-2), with 48.7% of users achieving ≥20% reduction. This exceeded semaglutide's typical 12-17% losses. The dual GLP-1/glucagon mechanism accounts for superior weight loss and metabolic improvements.
Why does mazdutide cause thermogenesis while semaglutide doesn't?+
Mazdutide's glucagon receptor agonism increases energy expenditure and thermogenesis—burning calories actively rather than just reducing appetite. Semaglutide is GLP-1 only. This dual-agonist approach explains mazdutide's superior metabolic rate elevation.
Is mazdutide safer than semaglutide for nausea?+
Not necessarily. Both cause GLP-1-induced nausea early in treatment, though it typically improves with dose escalation. Mazdutide's additional heart rate increase (5-17 bpm) from glucagon agonism is a distinct side effect requiring cardiovascular monitoring.
Can I switch from semaglutide to mazdutide?+
Potentially, but with medical supervision. Both are GLP-1 agonists, so overlap during transition risks hypoglycemia and severe GI effects. Wait 1-2 weeks after stopping semaglutide before starting mazdutide, and monitor glucose carefully. Never combine them.
References
Peptídeos relacionados
5-Amino-1MQ
PreclinicalNNMT Inhibitor | Longevity & Metabolic Enhancement
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.
AOD-9604
Well studiedModified hGH Fragment | Fat Loss Peptide
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone.
BAM-15
Moderate researchMitochondrial Uncoupler | Metabolic Enhancer
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders.
Cagrilintide
Extensively studiedLong-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes.